What is Speclipse?
Established in 2015 and co-headquartered in Sunnyvale, California, and Seoul, South Korea, Speclipse was founded by Sung Hyun Pyun, a Stanford University graduate and former Boston Consulting Group consultant. The company has garnered international recognition for its technological advancements, notably being the sole Korean entity recognized as a Dermatology Solution Provider by Medtech Outlook. Initially concentrating on skin cancer diagnostics, Speclipse is strategically broadening its business scope to encompass blood analysis, positioning itself at the forefront of innovative healthcare solutions. The company's trajectory is supported by a robust investor base, including prominent biotech venture capital firms.
How much funding has Speclipse raised?
Speclipse has raised a total of $7.7M across 1 funding round:
Unspecified
$7.7M
Unspecified (2021): $7.7M with participation from MiCoBioMed, BNH Investment, Signite Partners, Shinhan Capital, and MiCo
Key Investors in Speclipse
MiCoBioMed
MiCoBioMed is an investor participating in the funding round, likely focused on biomedical technologies and innovations within the healthcare sector.
BNH Investment
BNH Investment is a financial backer contributing to Speclipse's growth, potentially specializing in early-stage or growth-stage technology companies.
Signite Partners
Signite Partners is an investment firm that has provided capital to Speclipse, likely with an interest in innovative companies within the life sciences or technology industries.
What's next for Speclipse?
With the infusion of major enterprise-level capital and a recent strategic investment, Speclipse is poised for accelerated growth and innovation. The company's expansion from skin cancer diagnostics to blood analysis indicates a strategic diversification aimed at capturing a larger share of the burgeoning medtech market. Future developments are likely to focus on scaling its diagnostic platforms, further research and development into blood analysis technologies, and potentially expanding its global footprint. The backing from specialized biotech investors suggests a strong confidence in Speclipse's long-term vision and its potential to disrupt existing healthcare paradigms.
See full Speclipse company page
